CME in Minutes: Education in Dermatology - Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

CME in Minutes: Education in Dermatology

Answers in CME

Science

Health & Fitness

Frequency: 1 episode/24d. Total Eps: 41

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Dermatology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives. Inspiring and engaging programs designed for dermatologists to cover the diagnosis, treatment, follow-up, and clinical management of various skin conditions. Earning your CME/CE credit has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.

Read moreCollapse

Site

RSS

Apple

Data updated on 07/11/2026

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

Spotify

No recent rankings available

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

No links shared by this podcast

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

To improve

Score global : 42%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

Uniting Forces in Resectable Cutaneous Squamous Cell Carcinoma: The Multidisciplinary Playbook

Thursday, November 5, 2026 • Duration 01:01:06

Please visit answersincme.com/860/MED-ONC-03731-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sunandana Chandra, MD, MS; Vishal A. Patel, MD; Vernon K. Sondak, MD; and Jessica Kalen, MD, FAAD. In this activity, experts in skin cancer discuss the current use of immunotherapy-based treatment approaches in resectable cutaneous squamous cell carcinoma (CSCC), with a focus on the role of dermatologists in the multidisciplinary team. Upon completion of this activity, participants should be better able to: Outline guideline-recommended clinical approaches for the management of patients with early-stage CSCC; Specify key real-world considerations that influence the appropriate use of neoadjuvant and adjuvant immunotherapy in resectable CSCC, within the context of multidisciplinary care; and Formulate a collaborative care plan that defines the roles and responsibilities of multidisciplinary team members to optimize outcomes for patients with resectable CSCC who are candidates for neoadjuvant and/or adjuvant immunotherapy. This activity is intended for US healthcare professionals only.

Read moreCollapse

Taking Control of Moderate to Severe Bullous Pemphigoid (BP): Expert Insights on Diagnosing BP and Targeting Type 2 Inflammation

Thursday, August 20, 2026 • Duration 14:56

Please visit answersincme.com/ZYD860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by April W. Armstrong, MD, MPH. In this activity, an expert in dermatology discusses best practices to diagnose and manage bullous pemphigoid (BP). Upon completion of this activity, participants should be better able to: Review the process for diagnosing patients with BP; Assess the evidence for the use of biologics targeting type 2 inflammation in the treatment of BP; and Outline the clinical implications of the evidence for the treatment of BP with biologics targeting type 2 inflammation.

Read moreCollapse

Conversations in Gene Expression–Based Testing: A Clinician’s Roadmap to Multidisciplinary Melanoma Care

Thursday, August 13, 2026 • Duration 22:20

Please visit answersincme.com/GFY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vishal A. Patel, MD; and Jonathan S. Zager, MD, FACS, FSSO. In this activity, experts in cutaneous oncology discuss the evolving role of gene expression profiling (GEP) tests in refining risk assessment and supporting individualized, multidisciplinary management strategies for patients with melanoma. Upon completion of this activity, participants should be better able to: Identify the clinical rationale for using GEP tests to stratify the risk of disease progression in patients with cutaneous melanoma; Review the clinical evidence, including guideline-supported data, for GEP tests to stratify disease progression risk in patients with cutaneous melanoma; Formulate multidisciplinary strategies for incorporating the results of GEP tests into risk-based management of patients with cutaneous melanoma; and Outline patient-centered approaches to integrating GEP tests into the management of patients with cutaneous melanoma at risk of metastasis.

Read moreCollapse

Earlier Biologic Use, Better Pediatric AD Control: Advancing Shared Decision-Making for Enhanced Long-Term Outcomes

Wednesday, August 12, 2026 • Duration 28:14

Please visit answersincme.com/WWD860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Peter Lio, MD, FAAD; Sarah L. Chamlin, MD; and Heather Moery. In this activity, experts in pediatric atopic dermatitis discuss earlier use of systemic therapy to improve long-term disease control and patient-centered outcomes. Upon completion of this activity, participants should be better able to: Identify the need for systemic therapy among pediatric patients with moderate-to-severe atopic dermatitis (AD); Recognize pediatric patients with moderate-to-severe AD for whom biologic therapy is an appropriate, evidence-based option; Review shared decision-making considerations regarding biologic therapy for pediatric patients with moderate-to-severe AD; and Integrate strategies to optimize biologic treatment for pediatric patients with moderate-to-severe AD.

Read moreCollapse

From Surgery to Systemic Therapy: A Collaborative Discussion on CSCC Neoadjuvant and Adjuvant Immunotherapy

Wednesday, July 29, 2026 • Duration 01:08:28

Please visit answersincme.com/860/MED-ONC-03814-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Neil D. Gross, MD, FACS; Nikhil I. Khushalani, MD; and Emily S. Ruiz, MD, MPH. In this activity, leading skin cancer experts guide an interactive, multidisciplinary case-based discussion on optimizing (neo)adjuvant immunotherapy for high-risk, resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Apply the latest clinical trial data and guideline recommendations to treatment planning for patients with high-risk, resectable CSCC; Recognize when to incorporate systemic neoadjuvant and adjuvant immunotherapy in patients with CSCC based on clinical and pathological features; and Propose strategies to optimize care for patients with high-risk CSCC through the evidence-based use of neoadjuvant and adjuvant immunotherapy within multidisciplinary care plans.

Read moreCollapse

It’s Not "Just Hives": Advancing Targeted Care in Chronic Spontaneous Urticaria

Tuesday, July 28, 2026 • Duration 01:02:14

Please visit answersincme.com/860/2026-MC-001884-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Marc Serota, MD; Kristin Sokol, MD, MS, MPH; and Michelle Tarbox, MD. In this activity, experts in chronic spontaneous urticaria (CSU) discuss strategies to reduce diagnostic delays and how to personalize care beyond antihistamines. Upon completion of this activity, participants should be better able to: Recognize the impact of delayed diagnosis on disease control in patients with CSU; Review key inflammatory pathways—including type 2 inflammation—in CSU pathogenesis and how targeted therapies modulate them; Assess the latest clinical data for targeted therapies for the treatment of CSU; and Apply evidence-based strategies to personalize the management of antihistamine-refractory CSU.

Read moreCollapse

Transforming Outcomes for Patients With Chronic Spontaneous Urticaria: A New Era of Targeted Therapy

Friday, July 10, 2026 • Duration 16:21

Please visit answersincme.com/REE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Adam Friedman, MD. In this activity, an expert in the management of chronic spontaneous urticaria (CSU) discusses how targeted therapies fit within evolving treatment algorithms and how to integrate them appropriately into clinical practice for improved patient outcomes. Upon completion of this activity, participants should be better able to: Evaluate the rationale for targeted therapies in patients with CSU; Outline the different pathogenic mechanisms in CSU, with a focus on their relationship to type 2 inflammation, and the clinical implications of these different pathways; and Design treatment plans that optimize the use of targeted therapies in CSU, based on the latest evidence and expert insights.

Read moreCollapse

From Evidence to Action: Expert Dialogues on the Evolving Role of Immunotherapy in Basal Cell Carcinoma

Wednesday, July 1, 2026 • Duration 18:18

Please visit answersincme.com/UZA860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Anne Lynn S. Chang, MD and Zeynep Eroglu, MD. In this activity, experts in nonmelanoma skin cancer discuss clinical advances for the use of immunotherapy for the management of basal cell carcinoma (BCC). Upon completion of this activity, participants should be better able to: Evaluate current guideline-based recommendations for the use of immunotherapy in the management of basal cell carcinoma (BCC) across various stages of disease; Apply evidence-driven criteria to identify patients with BCC who may be appropriate candidates for immunotherapeutic intervention; and Determine real-world clinical approaches to optimize the benefit-risk profiles of immunotherapy in the management of BC.

Read moreCollapse

From Symptoms to Stability: Emerging OX40/OX40L‐Targeted Therapies, Durable AD Control, and Enhanced Quality of Life

Tuesday, June 30, 2026 • Duration 01:01:06

Please visit answersincme.com/860/2026-MC-001755-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Linda Stein Gold, MD and Stephan Weidinger, MD, PhD. In this activity, experts in dermatology discuss the rationale and emerging clinical data supporting the use of OX40/OX40L inhibitors for the treatment of moderate to severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Specify the rationale for targeting the OX40/OX40L pathway to achieve durable response in the treatment of moderate to severe atopic dermatitis (AD); Review the evidence on efficacy outcomes and safety profiles of the emerging OX40/OX40L inhibitors in AD management, including quality of life (QoL) impact; and Integrate QoL assessments into shared decision-making with patients who have moderate to severe AD.

Read moreCollapse

Redefining Oral Therapy in Psoriasis: TYK2 Inhibition in Focus

Monday, June 29, 2026 • Duration 01:01:09

Please visit answersincme.com/860/IME-020568-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jeffrey M. Cohen, MD, MPH; Kristine Kucera, PA-C, MPAS, DHSc; and Lauren E. Miller, MPAS, PA-C. In this activity, experts in dermatology discuss the evolving role of next-generation TYK2 inhibitors in the treatment of patients with moderate to severe psoriasis. Upon completion of this activity, participants should be better able to: Explain the clinical rationale for TYK2 inhibitors in the management of patients with moderate to severe psoriasis; Differentiate the mechanism of action of TYK2 inhibition from other oral treatment options used for patients with moderate to severe psoriasis; and Apply available clinical evidence to identify patients with moderate to severe plaque psoriasis who may be appropriate candidates for TYK2 inhibitor therapy within current treatment paradigms. This activity is intended for US healthcare professionals only.

Read moreCollapse

CME in Minutes: Education in Dermatology - Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

CME in Minutes: Education in Dermatology - Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Apple Podcasts

Spotify